BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 26823891)

  • 1. KRAS mutation-positive bronchial surface epithelium (BSE)-type lung adenocarcinoma with strong expression of TTF-1: a case providing a further insight as for the role of TTF-1 in the oncogenesis.
    Takanashi Y; Tajima S; Hayakawa T; Neyatani H; Funai K
    Int J Clin Exp Pathol; 2015; 8(11):15338-43. PubMed ID: 26823891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-terminal respiratory unit type lung adenocarcinoma has three distinct subtypes and is associated with poor prognosis.
    Sumiyoshi S; Yoshizawa A; Sonobe M; Kobayashi M; Sato M; Fujimoto M; Tsuruyama T; Date H; Haga H
    Lung Cancer; 2014 Jun; 84(3):281-8. PubMed ID: 24725383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
    Thomas A; Chen Y; Steinberg SM; Luo J; Pack S; Raffeld M; Abdullaev Z; Alewine C; Rajan A; Giaccone G; Pastan I; Miettinen M; Hassan R
    Oncotarget; 2015 May; 6(13):11694-703. PubMed ID: 26028668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Value of Cytokeratin 5/6, p63 and Thyroid Transcription Factor-1 in Adenocarcinoma, Squamous Cell Carcinoma and Non-Small-Cell Lung Cancer of the Lung.
    Argon A; Nart D; Veral A
    Turk Patoloji Derg; 2015; 31(2):81-8. PubMed ID: 25944390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological, immunohistochemical, and mutational analyses of pulmonary enteric adenocarcinoma: usefulness of SATB2 and β-catenin immunostaining for differentiation from metastatic colorectal carcinoma.
    Matsushima J; Yazawa T; Suzuki M; Takahashi Y; Ota S; Nakajima T; Yoshino I; Yokose T; Inoue T; Kawahara K; Nakatani Y
    Hum Pathol; 2017 Jun; 64():179-185. PubMed ID: 28438615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A resectable pancreatic metastasis from pulmonary adenocarcinoma.
    Igai H; Kamiyoshihara M; Nagashima T; Ohtaki Y; Shimizu K
    Ann Thorac Cardiovasc Surg; 2014; 20(3):243-5. PubMed ID: 23364227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment.
    Chung KP; Huang YT; Chang YL; Yu CJ; Yang CH; Chang YC; Shih JY; Yang PC
    Chest; 2012 Feb; 141(2):420-428. PubMed ID: 21799026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomorphologic overlap of differentiated thyroid carcinoma and lung adenocarcinoma and diagnostic value of TTF-1 and TGB on cytologic material.
    Sathiyamoorthy S; Maleki Z
    Diagn Cytopathol; 2014 Jan; 42(1):5-10. PubMed ID: 23637102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid transcription factor-1-regulated microRNA-532-5p targets KRAS and MKL2 oncogenes and induces apoptosis in lung adenocarcinoma cells.
    Griesing S; Kajino T; Tai MC; Liu Z; Nakatochi M; Shimada Y; Suzuki M; Takahashi T
    Cancer Sci; 2017 Jul; 108(7):1394-1404. PubMed ID: 28474808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivating mutations and hypermethylation of the NKX2-1/TTF-1 gene in non-terminal respiratory unit-type lung adenocarcinomas.
    Matsubara D; Soda M; Yoshimoto T; Amano Y; Sakuma Y; Yamato A; Ueno T; Kojima S; Shibano T; Hosono Y; Kawazu M; Yamashita Y; Endo S; Hagiwara K; Fukayama M; Takahashi T; Mano H; Niki T
    Cancer Sci; 2017 Sep; 108(9):1888-1896. PubMed ID: 28677170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
    Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid transcription factor 1 in pulmonary adenocarcinoma.
    Stenhouse G; Fyfe N; King G; Chapman A; Kerr KM
    J Clin Pathol; 2004 Apr; 57(4):383-7. PubMed ID: 15047742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysis.
    Kadota K; Nitadori J; Rekhtman N; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2015 Sep; 39(9):1170-80. PubMed ID: 25871623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDX-2 Expression in Primary Lung Adenocarcinoma.
    Cowan ML; Li QK; Illei PB
    Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):16-9. PubMed ID: 26469326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?
    Vincenten JP; Smit EF; Grünberg K; Postmus PE; Snijders PJ; Witte BI; Heideman DA; Thunnissen E
    Lung Cancer; 2015 Jul; 89(1):19-26. PubMed ID: 25982011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
    Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
    J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IMP3 can predict aggressive behaviour of lung adenocarcinoma.
    Beljan Perak R; Durdov MG; Capkun V; Ivcevic V; Pavlovic A; Soljic V; Peric M
    Diagn Pathol; 2012 Nov; 7():165. PubMed ID: 23190601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GATA6-positive lung adenocarcinomas are associated with invasive mucinous adenocarcinoma morphology, hepatocyte nuclear factor 4α expression, and KRAS mutations.
    Nakajima N; Yoshizawa A; Nakajima T; Hirata M; Furuhata A; Sumiyoshi S; Rokutan-Kurata M; Sonobe M; Menju T; Miyamoto E; Chen-Yoshikawa TF; Date H; Haga H
    Histopathology; 2018 Jul; 73(1):38-48. PubMed ID: 29469192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of p63, TTF-1 and Maspin in Non-Small Cell Lung Carcinoma and Their Effect on the Prognosis and Differential Diagnosis.
    Yaman B; Nart D; Ekren PK; Çok G; Veral A
    Turk Patoloji Derg; 2015; 31(3):163-74. PubMed ID: 26456962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.